Subscribe To
CGTX / Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD/PD 2023
CGTX News
By Seeking Alpha
August 12, 2023
Cognition Therapeutics, Inc. (CGTX) Q2 2023 Earnings Call Transcript
Cognition Therapeutics, Inc. (NASDAQ:CGTX ) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Daniel Kontoh-Boateng - In more_horizontal
By GlobeNewsWire
June 27, 2023
Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023
NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing drugs that t more_horizontal
By GlobeNewsWire
March 21, 2023
Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD/PD 2023
- CEO Participating on Panel Hosted by Alzheimer's Drug Discovery Foundation - - CEO Participating on Panel Hosted by Alzheimer's Drug Discovery Found more_horizontal
By GlobeNewsWire
March 16, 2023
UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
Conference Call and Live Audio Webcast Scheduled for Thursday, March 23, 2023, 8:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for Thurs more_horizontal
By GlobeNewsWire
May 4, 2022
CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022
PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cognition Therapeutics, Inc. (NASDAQ: CG more_horizontal
By Seeking Alpha
March 30, 2022
Cognition Therapeutics, Inc. (CGTX) CEO Lisa Ricciardi on Q4 2021 Results - Earnings Call Transcript
Cognition Therapeutics, Inc. (CGTX) CEO Lisa Ricciardi on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Market Watch
October 8, 2021
Cognition Therapeutics raised more than $45 million after IPO priced in the middle of the expected range
Cognition Therapeutics Inc.'s stock CGTX, is set to start trading Friday, after the New York-based biopharmaceutical company targeting treatments for more_horizontal
By Market Watch
October 8, 2021
Cognition Therapeutics raised more than $45 million after IPO priced in the middle of the expected range
Cognition Therapeutics Inc.'s stock CGTX, is set to start trading Friday, after the New York-based biopharmaceutical company targeting treatments for more_horizontal
